Welcome to the Weill Cornell Institutional Review Board

The Weill Cornell Medicine Institutional Review Board (WCM-IRB) is an appropriately constituted group whose primary responsibility is to ensure that the rights and welfare of human subjects in research are protected.  In doing so, the IRB must ensure all human subject research activities are conducted ethically, and in compliance with Federal regulations, the requirements of applicable New York State and local laws, and institutional policies and procedures. In accordance with the Common Rule and FDA regulations, the IRB has responsibility for approving, modifying, and/or disapproving human subject research. The IRB also has the authority to suspend or terminate research in order to protect research subjects and for noncompliance with applicable rules and regulations.

As part of the IRB’s partnership with the research community in the ethical conduct of human subjects research, this website acts as the entry point to IRB resources at Weill Cornell Medicine.

Working on an Industry-Initiated and -Funded Trial?

WCM is requiring that industry-initiated and -funded trials with a commercial IRB designated by the industry sponsor use that commercial IRB (e.g., WCG, Advarra, BRANY).

If an industry-initiated and -funded trial does not have a designated IRB, it will be sent to BRANY.

Where would you like to go today?

Research Team Resources buttonIRB Member Resourcesicon of three peopleIRB Staff Resources

Looking for the WCM-Qatar IRB?


October 2022 Newsletter

Submitting a New IRB Application?

As of 9/15/2022, all new applications must utilize the new IRB Initial...

September 2022 Newsletter

The New IRB Initial Review Application is live! 

We are excited to announce that the New IRB Initial Review...

IRB Newsletter August 15, 2022

BRANYplus extended through Fall 2022; The New IRB Initial Review Application: Launching 9/15/22

In response...